PREVALENCE AND IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS WITH LOW ECONOMIC STATUS

Nishitha Chowdary Dl; Somasundaram I

doi:10.22159/ajpcr.2018.v11i6.21752

Authors

Nishitha Chowdary Dl Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Vels University, Chennai, Tamil Nadu, India.
Somasundaram I Department of Parmacetics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Vels University, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.21752

Keywords:

Painful diabetic peripheral neuropathy, Type-2 diabetes, Questionnaire, Quality of life, Patient counseling

Abstract

Objectives: The objectives of the study were to study the prevalence of painful diabetic peripheral neuropathy (PDPN) in patients with type-2 diabetes and to access the health-related quality of life of patient by collecting and documenting the information of patient using sf-15 questionnaire.

Methods: The present study involves prospective analysis of quality of life in both men and women with PDPN with type-2 diabetes. The methodology involves collection and documentation of patients medical and medication history, blood glucose levels, and duration of diabetes. Further, the quality of life of patient is documented using Michigan neuropathic scaling instrument (sf-15 questionnaire) through which we can assess the impact of PDPN.

Results: It can be seen that there are no significant changes in the prevalence of PDPN when compared gender wise and based on age, but there are an extremely statistically significant (*p<0.05) values obtained when the presence of PDPN is compared between duration of diabetes.

Conclusion: Patients with duration of diabetes type-2 between 5 and 10 years are mostly presented with PDPN. Early detection, nutritious diet, and patient counseling help in management of PDPN.

Downloads

Download data is not yet available.

References

Seema T, Neha S. Update on neuropathic pain models. Int J Pharm Pharm Sci 2016;8:11-6.

Senthilkumar, Anandhasayanam A, Safil KM, Shemimol S. Comparative study on the effectiveness of angiotensin converting enzyme inhibitors (aceis) and angiotensin receptor blockers (arbs) in diabetic nephropathy in Type 2 diabetes mellitus patients. Int J Pharm Pharm Sci 2016;8:289-92.

Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. Int J Clin Pract 2007;62:76-87.

Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. A review article based on peripheral neuropathy. Diabetes 1997;46 Suppl 2:54S-7.

Greenbaum D. Observations on the homogeneous nature and pathogenesis of diabetic neuropathy. Brain 1964;87:215-32.

Thomas PK, Griffin JW. Neuropathies predominantly affecting sensory or motor function. In: Peripheral Nerve Disorders. Oxford: Butterworths; 1995. p. 59-94.

Mahajan R, Gupta K. Revisiting metformin: Annual vitamin B12 supplementation may become mandatory with long-term metformin use. J Young Pharm 2010;2:428-9.

Farouk AS, Alkandri ME, Al-Hashel JM, Alhajerie D, Alroughani R. Prevalence and treatment options for diabetic neuropathic pain in Kuwait. Neurology 2017;88:16.

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A, et al. Prevalence and risk factors of development of peripheral diabetic neuropathy in Type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig 2014;5:714-21.

Jayaprakash P, Bhansali A, Bhansali A, Dutta P, Anantharaman R, Shanmugasundar G, et al. Validation of bedside methods in evaluation of diabetic peripheral neuropathy. Indian J Med Res 2011;133:645-9.

Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-7.

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012;28 Suppl 1:8-14.

Al-Geffari M. Comparison of different screening tests for diagnosis of diabetic peripheral neuropathy in primary health care setting. Int J Health Sci (Qassim) 2012;6:127-34.

Swislocki A, Orth M, Bales M, Weisshaupt J, West C, Edrington J, et al. A randomized clinical trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manage 2010;39:88-99.

Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.

Schmader KE. Epidemiology and impact on quality of life of post herpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.

Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8.